RxDoctor Payments Data

Jeannie Franklin

Clinical Nurse Specialist · Sioux City, IANPI 1679813976

Payments from drug & device makers

$5,056in general payments, 2019–2025

Across 297 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$714
  • Otsuka America Pharmaceutical, Inc.$588
  • Johnson & Johnson$513
  • Lundbeck LLC$471
  • AbbVie$467
  • Teva Pharmaceuticals USA, Inc.$410
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,00999%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical nurse specialist providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$32,100
Medicare patients
120
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AristadaAripiprazole Lauroxil27$92,147
VraylarCariprazine Hcl27$37,876
TrintellixVortioxetine Hydrobromide28$15,336
Lisdexamfetamine Dimesylate39$10,348
VyvanseLisdexamfetamine Dimesylate27$9,844
BelsomraSuvorexant20$8,927
FetzimaLevomilnacipran Hcl14$6,995
Adderall XrDextroamphetamine/Amphetamine16$5,166
Clozapine18$4,495
Paliperidone ErPaliperidone29$4,016
Quetiapine Fumarate273$3,792
Aripiprazole148$3,312
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine48$3,074
Ziprasidone Hcl75$2,970
Lurasidone Hcl21$2,914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada$714$92,14727 claims
AbbVieVraylar, Fetzima$467$44,87141 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$131$25,18155 claims
MerckBelsomra$64$8,92720 claims
Almatica Pharma LLCSertraline Hcl$46$1,055124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical nurse specialist providers in Iowaon file to place this against a meaningful peer group, so we don't.

Other clinical nurse specialist in Sioux City

Where these figures come from

Is this you, or does something look wrong? →